Apertura Gene Therapy Deal History & Licensing Activity
Apertura Gene Therapy is a biotech. Over the past three years, Apertura Gene Therapy has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Rare Disease
Apertura Gene Therapy Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Apertura Gene Therapy in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TfR1 CapX™ | Foundation for Angelman Syndrome Therapeutics (FAST) | Gene Therapy | Preclinical | license | Aug 5, 2026 |
| TfR1 CapX | NIH (NICHD and NHGRI) | Gene Therapy | Preclinical | collaboration | Jul 9, 2026 |
Apertura Gene Therapy Pipeline Focus
Therapeutic areas and modalities where Apertura Gene Therapy is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Apertura Gene Therapy Strategic Signals
Key indicators of Apertura Gene Therapy's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Apertura Gene Therapy's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Apertura Gene Therapy Licensing & Deal Activity
Apertura Gene Therapy is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Apertura Gene Therapy ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Apertura Gene Therapy include Rare Disease (4 deals and trials). In terms of modality, Apertura Gene Therapy has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Apertura Gene Therapy and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Apertura Gene Therapy's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.